These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26214804)

  • 1. The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study.
    Tamura H; Goto R; Akune Y; Hiratsuka Y; Hiragi S; Yamada M
    PLoS One; 2015; 10(7):e0133628. PubMed ID: 26214804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of screening programs for age-related macular degeneration: amended Japanese specific health checkups and augmented screening programs with OCT or AI.
    Tamura H; Akune Y; Hiratsuka Y; Kawasaki R; Kido A; Miyake M; Goto R; Yamada M
    Jpn J Ophthalmol; 2022 Jan; 66(1):19-32. PubMed ID: 34993676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Sharma S; Brown GC; Brown MM; Hollands H; Shah GK
    Ophthalmology; 2001 Nov; 108(11):2051-9. PubMed ID: 11713079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Screening for Intermediate Age-Related Macular Degeneration during Diabetic Retinopathy Screening.
    Chan CK; Gangwani RA; McGhee SM; Lian J; Wong DS
    Ophthalmology; 2015 Nov; 122(11):2278-85. PubMed ID: 26315045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.
    Karnon J; Czoski-Murray C; Smith K; Brand C; Chakravarthy U; Davis S; Bansback N; Beverley C; Bird A; Harding S; Chisholm I; Yang YC
    Health Technol Assess; 2008 Jun; 12(27):iii-iv, ix-124. PubMed ID: 18513468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
    Wolowacz SE; Roskell N; Kelly S; Maciver FM; Brand CS
    Pharmacoeconomics; 2007; 25(10):863-79. PubMed ID: 17887807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea.
    Ra H; Song LD; Choi JA; Jee D
    PLoS One; 2018; 13(10):e0206690. PubMed ID: 30379971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of screening for diabetic retinopathy in Japan: a probabilistic Markov modeling study.
    Kawasaki R; Akune Y; Hiratsuka Y; Fukuhara S; Yamada M
    Ophthalmic Epidemiol; 2015 Feb; 22(1):4-12. PubMed ID: 25517603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan.
    Yanagi Y; Fukuda A; Barzey V; Adachi K
    J Med Econ; 2017 Feb; 20(2):204-212. PubMed ID: 27701921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR; Moride Y; Rochon S
    Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
    Karel I
    Cesk Slov Oftalmol; 2007 Sep; 63(5):311-9. PubMed ID: 17915581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuity.
    Butt T; Patel PJ; Tufail A; Rubin GS
    Appl Health Econ Health Policy; 2014 Jun; 12(3):289-97. PubMed ID: 24610632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis.
    Hernandez L; Lanitis T; Cele C; Toro-Diaz H; Gibson A; Kuznik A
    J Manag Care Spec Pharm; 2018 Jul; 24(7):608-616. PubMed ID: 29952707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
    Hernández-Pastor LJ; Ortega A; García-Layana A; Giráldez J
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
    Colquitt JL; Jones J; Tan SC; Takeda A; Clegg AJ; Price A
    Health Technol Assess; 2008 May; 12(16):iii-iv, ix-201. PubMed ID: 18462575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
    Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
    Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
    Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
    J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.